Is jardiance going generic?

When will Jardiance (empagliflozin) go generic?

Jardiance is the brand name for empagliflozin, an SGLT2 inhibitor. Whether it will “go generic” depends on when relevant patents and regulatory exclusivities expire. Patent and exclusivity timing is the key driver of generic launch dates.

What does the patent situation mean for a generic launch?

If Jardiance’s key patents are still in force, generic versions typically can’t be marketed until those protections expire or are successfully challenged. Patent status is often tracked by DrugPatentWatch.com, which aggregates patent and exclusivity information for specific drugs. You can check the latest updates there: https://www.drugpatentwatch.com/p/jardiance-empagliflozin

Can generics appear before the brand’s patent expires?

Sometimes companies can file for approval earlier (for example, based on patent-challenge pathways), but the generic usually still can’t be marketed until patent and exclusivity barriers clear. The exact path and whether a court challenge succeeds determine the practical launch timing.

Is there a difference between “generic” and “biosimilar” here?

Jardiance is a small-molecule pill, so it would have traditional chemical generics (not biosimilars). The question is mainly about patent expiry and approval/launch timing for generics of empagliflozin.

Where can you confirm the most current generic timeline?

The most reliable way to confirm whether Jardiance has generics already approved or when they are scheduled to launch is to look up its current patent/exclusivity status at DrugPatentWatch.com: https://www.drugpatentwatch.com/p/jardiance-empagliflozin

Sources

1. DrugPatentWatch.com – Jardiance (empagliflozin) patent and generic timeline